Kornimate/medical-research-clean huggingface dataset:
low level light therapy (lllt) for hair growth

Conditions: Male Pattern Baldness; Female Pattern Baldness

Summary: a total of 62 participants will receive red light (660 nm) to the scalp through a specially designed light therapy device integrated into a conventional hat. each treatment will be 30 min per session applied on every other day for 14 weeks.


Eligibility criteria:
inclusion criteria: * male or female subjects between the ages of 18 and 60 years * diagnosed aga in the past 12 months for male (fitzpatrick i-iv, hamilton-norwood iia-v ) and female (fitzpatrick i-iv, and ludwig-savin baldness scale i-2, i-3, i-4, ii-1, ii-2 baldness patterns) exclusion criteria: * known photosensitivity * using any oral or topical substance for hair growth * having tattoo, hair transplantation, scalp reduction, malignancy or hair weave in the scalp are with alopecia * known medical conditions that could negatively affect hair growth, such as infections, connective tissue disease * currently or plan to be on a calorie-restricted diet during study participation
effects of sub-occipital myofascial release in patients with cervicogenic headache

Conditions: Cervicogenic Headache

Summary: cervicogenic headache is a secondary form of headache that occurs from the upper cervical spine and atlanto-occipital joint. a cgh is a frequent source of chronic headache and is frequently misdiagnosed .cervicogenic headache is among the most common problem affecting four times more women as compared to males and is considered by some painful feeling in the head , neck ,temporal area, frontal area and around the eyes areas.

there is also pain in the face and ipsilateral head that does not alternate the sides, but when cervicogenic headache becomes severe, in some patients pain may occasionally feel it on the other side of the head. diagnosis of cervicogenic headache depends on the detailed patient's history, manual examination and the assessment of nervous system. after the diagnostic block test disappearance of headache shows that the source of this pain is cervical spine. cervical flexion rotation test is a very useful diagnostic measure in cervical movement restriction and differential diagnosis of cervicogenic headache. physical therapy is considered most effective treatment of cervicogenic headache in which different techniques manipulative therapy, mobilization of cervical vertebrae, stretches and sub-occipital myofascial release used. objective: to determine the effects of sub-occipital myofascial release in patients with cervicogenic headache. methods: this study was randomized control trial and on the basis of inclusion criteria, 22 patients were included and were randomized through sealed envelope in two groups a and b. group a was given sub-occipital myofascial release along with conventional therapy while group b was given cervical mobilization and conventional therapy and both groups were assessed by using neck disability index(ndi), pain numerical rating scale(pnrs) and cervical range of motion by goniometer at baseline, week(1-4) and 8th week( last week) .the data was analyzed using spss 21.

Eligibility criteria:
inclusion criteria: * • both genders * age between 20 to 75 years * neck pain referring the unilateral pain to the sub-occipital region and head. * headache intensifying upon manual pressure to upper cervical joints and muscles * with the cranio-cervical flexion rotation exam, neck pain and ipsilateral headache and restriction of c1 and c2 rotation. exclusion criteria: * • tension headache (headache on both sides) * if the patient not tolerate the cranio-cervical flexion rotation test. * patients presents with autonomic symptoms like visual disturbance, vertigo, dizziness. * if the physiotherapeutic modalities used for head pain in the last 6 months. * headache other than cervical origins. * clinically diagnosed as case of cervical radiculopathy or myelopathy. * extreme cervical discomfort due to disk herniation, stenosis of the spinal canal and cervical arthritis. * each other disorder that may be contraindicated in the upper cervical area of myofascial release.

Keywords: cervicogenic headache pain numerical rating scale neck disability index
effects of fish oil and colesevelam (stair7007)

Conditions: Sitosterolemia

Summary: if treatment of colesevelam, fish oil in conjunction with ezetimibe, will lead to further reduction in plasma plant sterol levels in sitosterolemia patients. we hypothesize that treatments with fish oil, colesevelam and ezetimibe will maximize decrease in plasma concentrations of sitosterol and other plant sterols in sitosterolemia patients.

ezitimibe significantly lowers plant sterol levels in the blood of patients with sitosterolemia. however, plant sterol levels remain substantially elevated compared to those in healthy individuals. thus, combination therapy needs to be considered. agents that provide cardiovascular benefits such as colesevelam, a second-generation bile acid sequestrant, and fish oil are potential candidates to help further reduce sterol levels, but have yet to be evaluated in sitosterolemia patients. the purpose of this study is to dtermine the effects of colesevelam, fish oil and combination therapy (fish oil + colesevelam) on plant sterols, cholesterol and cardiovascular risk factors in sitosterolemia patients treated with ezetimibe. the results of this study will enhance knowledge on the pathogenesis of sitosterolemia and the mechanisim of actions of colesevelam and fish oil as adjunct therapies to ezitimibe in patients with the disease.

Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of homozygous sitosterolemia as established by genotyping and/or clinical parameters 2. receiving ezetimibe treatment 3. over 8 years of age (no maximum) 4. concomitant illnesses or conditions exclusion criteria: 1. pregnancy 2. intellectual disability 3. bowel or biliary obstruction 4. known hypersensitivity to colesevelam or any ingredients of colesevelam

Keywords: plant sterols cholesterol colesevelam phytosterolemia fish oil
minimally invasive simple hysterectomy in low risk cervical cancer

Conditions: Cervical Cancer; Cervix Cancer

Summary: the rationale of the present study is to assess the safety of the minimally invasive surgery approach in patients meeting the shape trial inclusion criteria.the shape trial was designed to answer the clinical question of whether simple hysterectomy could be performed instead of radical hysterectomy in low-risk early stage cervical cancer but not the surgical approach. the favorable oncological outcome observed in shape despite 75% of patients were treated with minimally invasive approach suggests that this approach may be safe. however, the trial was not designed to analyze oncological outcomes from surgical approach.

the laparoscopic approach to cervical cancer (lacc) trial showed that minimally invasive radical hysterectomy was associated with lower rates of disease-free survival and overall survival than open abdominal radical hysterectomy among women with early-stage cervical cancer. since then, the standard of care in terms of surgical approach to radical hysterectomy has been considered the laparotomy. more recently, the shape trial results were presented showing that in patients with low-risk cervical cancer (defined as figo 2018 stage ia2 and ib1 up to 2 cm, with limited stromal invasion: \< 10 mm on leep/cone and \< 50% depth on mri) simple hysterectomy was not inferior to radical hysterectomy for what concerned pelvic recurrence, with less complications and better quality of life. however, shape trial was not designed to assess the surgical approach. the rationale of the present study is to assess the safety of the minimally invasive surgery approach in patients meeting the shape trial inclusion criteria.

Eligibility criteria:
inclusion criteria: * squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma of uterine cervix * figo 2018 stage ia2-ib1 (≤2cm) with depth of infiltration ≤10mm on conization specimen * figo 2018 stage ia2-ib1 (≤2cm) with depth of infiltration ≤50% at pre-conization mri-scan or "expert" us-scan. * age ≥18 years exclusion criteria: * neuroendocrine, clear cell, serous carcinoma * depth of infiltration \>10 mm on conization specimen * depth of infiltration \>50% at pre-conization imaging * cervical tumor \>2 cm * diagnosis on inadvertent hysterectomy * neoadjuvant chemotherapy * previous pelvic radiotherapy * pregnant women * contraindications to surgery * lymph nodes \>15 mm short axis * fertility sparing treatment or desire * recurrent cervical cancer * time between cervical cancer diagnosis and hysterectomy \>4 months if conization with tumor negative margins * time between cervical cancer diagnosis and hysterectomy \>3 months if conization with invasive tumor positive margins

Keywords: cervical cancer minimally invasive surgery in cervical cancer robotic surgery in cervical cancer laparoscopic surgery in cervical cancer lacc trial shape trial low risk cervical cancer
evaluation of surgical excision of cardiophrenic lymph nodes in patients with advanced ovarian cancer

Conditions: Ovarian Cancer

Summary: evaluation of surgical excision of cardiophrenic lymph nodes in patients with advanced ovarian cancer

the role of cardiophrenic lymph node assessment and excision in advanced ovarian cancer is still debatable , correlation of radiological finding with pathological findings after reaction of radiological positive lymph nodes and its impact in diseases free survival and over all survival

Eligibility criteria:
inclusion criteria * ovarian cancer patient (figo stage iii-iv) * preoperative ct showing cpln with short axis diameter \> 5mm. * anathestically fit patient (asa score i or ii). * accepted pulmonary function test. * patient who received neoadjuvant chemotherapy or recurrent cases may be enrolled * written informed consent. * achievement of optimal cytoreduction intra-abdominal( no residual disease more than 1 cm ) exclusion criteria: * anathestically unfit patient * unresectable disease * patient refusal * no detected cpln by preoperative radiology
clinical predictive factors of success of hysteroscopic endometrial ablation/resection

Conditions: Uterine Bleeding; Treatment Failures; Prognostic Factors

Summary: to determine the predictive factors of endometrial ablation failure in the management of uterine bleeding.

this is a retrospective cohort study for women who have been treated with thermal endometrial ablation due to uterine bleeding. the main purpose of this study is to demonstrate the possible risk factors associated with endometrial ablation failure causing patients to need subsequent gynecological procedures or undergoing hysterectomy for definitive treatment. such efforts are made in order to anticipate the morbidity and mortality associated with patients in such conditions and to effectively stratify those patients to appropriate treatment techniques.

Eligibility criteria:
inclusion criteria: * all patients who had their endometrial ablation at jordan university hospital. exclusion criteria: * patients whose index ablation or subsequent re-intervention could not be confirmed in detailed operative reports were excluded

Keywords: endometrial ablation technique uterine bleeding treatment failures prognostic factors
a study looking at how insulin icodec is taken up in the blood when administered in different injection sites in people with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this study is comparing the concentration of a single dose of insulin icodec when administered in the belly, upper arm and thigh on different occasions. participants will receive one injection of insulin icodec on three different occasions, each time injected at a different site, i.e. either on our belly, upper arm or thigh. the study will last for about 34 weeks. participants will have 23 visits with the study doctor. informed consent (v0) visit and screening visit (v1) will be performed on two different days. the informed consent visit may be performed via telephone to minimize personal contact with site staff during the coronavirus outbreak. women cannot take part if pregnant, breast- feeding or plan to become pregnant during the study period.


Eligibility criteria:
inclusion criteria: * male or female * aged 18-69 years (both inclusive) at the time of signing informed consent * body mass index between 18.5 and 38.0 kg/m\^2 (both inclusive) * diagnosed with type 2 diabetes mellitus above or equal to 180 days prior to the day of screening * hba1c (glycated haemoglobin) below or equal to 9.0 percentage at screening * current daily basal insulin treatment of 0.2-1.0 (i)u/kg/day (both inclusive) with or without any of the following anti-diabetic drugs/regimens with stable doses above or equal to 90 days prior to the day of screening: * any metformin formulation * other oral antidiabetic drugs: dpp-4 inhibitors / sglt2 inhibitors / oral combination products (for the allowed individual oral antidiabetic drugs) * oral or injectable glp-1 (glucagon-like peptide 1) receptor agonists exclusion criteria: * known or suspected hypersensitivity to trial product(s) or related products. * female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice).
is mio-rsa noninferior to bio-rsa when it comes to mechanical implant stability?

Conditions: Arthroplasty Complications; Shoulder Osteoarthritis

Summary: this clinical trial will investigate whether metallic lateralization in reverse shoulder arthroplasty is as stable as bony lateralization during the first two postsurgical years, measured with ct-based motion analysis (ctma).

lateralization of reverse shoulder arthroplasties may reduce the risk for complications such as limited range of motion (rom), and scapular notching, where the lower part of the scapular neck becomes eroded due to impingement against the humeral component. there's several ways to lateralize the glenoid component, a bone transplant placed underneath the glenoid component (bony increased offset reversed shoulder arthroplasty: bio-rsa) has been used for some time. recently glenoid components with metallic lateralization of the joint centre (metal-increased offset reversed shoulder arthroplasty: mio-rsa) have been introduced, but there is not much comparative literature on metal vs. bony lateralization. patients with osteoarthritis and medialization of the glenoid articular surface, who willing to participate in a study will be randomized to receive either mio-rsa or a bio-rsa. ct-based motion analysis (ctma) will be used to measure the 3-dimensional migration pattern of the glenoid components to assess the stability of the prostheses up to two years after implantation.

Eligibility criteria:
inclusion criteria: * eligible for primary rsa due to oa, massive rc tear, failed rc repair or post-instability osteoarthritis * massive glenoid medialization * able to read or write norwegian exclusion criteria: * severe osteoporosis * osteonecrosis of the humeral head * dementia * poor deltoid function * revision surgery * asa iv * suspected chronic infection * acute fracture

Keywords: reverse shoulder arthroplasty bio-rsa mio-rsa bony lateralization metallic lateralization orthopedic surgery
comparison of pesticide and pharmaceutical contaminants levels in placenta and cord blood samples of pregnant women with fetal growth retardation and healthy pregnant women

Conditions: Fetal Growth Retardation

Summary: aim: in this study, pesticide and pharmaceutical contaminants levels in the placenta and cord blood of pregnant women with fetal growth retardation and healthy pregnant women will be compared in placenta and cord blood samples after delivery.

the study will be conducted with a total of 40 pregnant women, 20 of whom are in the control groups and those with fgr diagnoses. cases in both groups will be matched in terms of demographic information. demographic information (including socioeconomic status, educational level, region of residence), ultrasound and doppler examination results, newborn weight at birth, apgar score, gender, mode of delivery, whether there is a need for neonatal intensive care or not will be recorded.

Eligibility criteria:
inclusion criteria: * between the ages of 18-40 years * gestational age between 320/7 - 396/7 weeks * singleton pregnancy * for the fgr group: estimated fetal weight \<10th percentile * for the control group: being healthy pregnant * intact amniotic membrane exclusion criteria: * multiple pregnancies * cardiovascular disease * chronic hypertension * autoimmune disease * intrahepatic cholestasis of pregnancy * preeclampsia-eclampsia * sepsis * placenta accreta spectrum * abnormalities of placenta * the chromosomal or congenital structural anomaly of the fetus * smoking * bmi \>30 kg/m2
coronavirus induced acute kidney injury: prevention using urine alkalinization

Conditions: COVID; Coronavirus; Coronavirus Infection; AKI; Acute Kidney Injury

Summary: our overarching goal is to improve the outcomes of critically ill covid-19 patients with or at risk for development of acute kidney injury (aki). the objective of this study is to determine the role of a protocol to manage urine alkalization using a simple medication that has been used for a very long time, is safe, and without significant side-effects. we aim to determine the feasibility and safety of a urine alkalinization protocol for the prevention of aki in patients testing positive for covid-19.

emerging evidence suggests that acute kidney injury (aki) secondary to covid-19 (cov-aki) might result from direct infection of renal tubule epithelial cells (rtec). a variety of epithelial cells express the ace2 receptor which contains the receptor-binding domain (rbd) used by sars-cov-1 and sars-cov-2 to enter the cells. while direct infection of rtec has not yet been proven data from multiple laboratories show virus in the kidney. it is this direct viral involvement of the rtec that this proposal seeks to address. one relatively simple approach would be to perturb the ability of the rbd to bind to its cellular (hace2) receptor. changes in ph may cause each amino acid residue, in the rbd, to assume a slightly different 'microscopic' conformation-dependent pka value. urine ph is normally 5.5- 6.5 (not too dissimilar to alveolar fluid-6.4-6.86) and can be easily and safely manipulated. in fact, urine alkalinization protocols have been used for decades to reduce renal toxicity from various compounds (especially chemotherapy) and are recommended by us and european toxicology societies. here, the strategy will be deployed not for ion trapping but to inhibit the virus from infecting rtec. alkalinizing the urine using iv sodium-bicarbonate solution to ph of 7.5 or more can be easily and safely achieved. while severe aki does not appear to be a major part of the sars-cov-2 syndrome for most patients, when severe aki does occur, mortality is very high and preventing early aki may reduce aki severity as the disease progresses.

Eligibility criteria:
inclusion criteria: * confirmed covid-19 positive * admission to icu or step-down unit * age ≥ 18 years old exclusion criteria: * stage 3 aki by kdigo criteria * ckd stage 4-5 * contraindications to na bicarbonate therapy (e.g. met. alkalosis, severe heart failure) * urine ph \> 7.0

Keywords: acute kidney injury aki covid-19 coronavirus sodium bicarbonate
the health-related quality of life in patients with hereditary multiple exostoses

Conditions: Exostoses, Multiple Hereditary

Summary: the purpose of this study is to assess the health-related quality of life of subjects who have hereditary multiple exostoses and to develop a disease specific quality of life survey. the investigators hypothesize that there are a wide range of quality of life experiences for patients with this syndrome.

at the time of recruitment, subjects will be asked to indicate whether they would like to participate in a one-time survey, or are willing to participate in the initial survey plus two additional questionnaire administrations, thereafter, which will be used to develop the disease-specific quality of life (qol) score. all participants will complete either the sf-36 survey (for adult hme subjects) or the chq pf (for parents of children with hme), as applicable, in addition to a blank form with categorical subheadings (such as recreation, social function, etc.), which they will use to address any issues not covered in the standardized questionnaire. standardized questionnaires will be scored and analyzed. the items listed on the second form will be compiled and reapplied to subjects that indicated interest in extended participation in survey completion. subjects will be asked to determine which items apply to them and to rank these applicable items in order of importance. the results from this will be used to develop a 30 question, disease-specific questionnaire. the final step will be to readminister this survey, in conjunction with the sf-36 or chq pf, and follow up, in two weeks, with a second administration of the aforementioned surveys, in order to test the variability and validity of the disease-specific, health-related, quality of life score.

Eligibility criteria:
inclusion criteria: * must be diagnosed with hereditary multiple exostoses * adult patients or parents of child patients

Keywords: hereditary multiple exostoses survey quality of life hereditary multiple exostoses, also known as multiple hereditary exostoses, also known as hereditary multiple osteochondromas
dose ranging study of ivermectin treatment conditioner in subjects with head lice infestation

Conditions: Pediculus Humanus Capitis (Head Lice)

Summary: this is a phase 2 single center study designed to compare the safety, local tolerability, and efficacy of 3 strengths of ivermectin treatment conditioner to placebo.


Eligibility criteria:
inclusion criteria: * subjects who are at least 6 months old and weighing at least 15 kg. * infestation with head lice and viable nits. * are otherwise in a normal state of health. * willing and able to attend all study visits as scheduled. * agree not to cut or chemically treat their hair in the period between treatment and the final visit. * the subject and/or his/her parent/legal guardian have provided written informed consent, and, if appropriate, the child has provided assent. * females of childbearing potential must have a negative urine pregnancy test at screening and agree to take reasonable precautions against becoming pregnant during the study period. exclusion criteria: * subjects who have received any over the counter or prescription treatment for head lice in the last 2 weeks. * subjects unable to comply with the study obligations and all study visits. * subjects with eczema or other chronic conditions of the scalp and skin. * subjects in a household with more than 5 infested members. * subjects with a history of allergy to ivermectin or any ingredients commonly included in hair products such as shampoos, hair conditioners, or styling aids. * subjects with neurologic conditions including a seizure disorder or history of seizures. * subjects with an infestation of body lice or pubic lice (determined by questioning). * subjects suffering from a condition likely to require medical attention, including administration of oral or systemic antibiotics, oral or systemic corticosteroids, or any other treatment, which in the opinion of the investigator and visiting physician could influence the results of the study. * subjects with other diagnoses which, in the opinion of the investigator, would interfere with efficacy or safety assessments or would preclude study participation. * subjects with very short (shaved) hair. * subjects who have been treated with a systemic antibiotic within the previous 2 weeks before screening. * subjects who have been previously enrolled in any clinical study within the past 30 days; subjects may not participate in another study while participating in this study. * pregnant and/or nursing females.

Keywords: head lice pediculus humanus capitis ivermectin